Latest News & Updates

Latest Articles
Harvard Expert Sees Potential in BCL-2 Combos
Anthony G. Letai, MD, PhD, discusses the complex nature of apoptosis and efforts to target the process.
PUBLISHED: May 27, 2018
Qualified Clinical Data Registries Help Practices Meet MIPS Requirements
To ease the administrative burden, CMS has facilitated the collection and processing of information by allowing the formulation of Qualified Clinical Data Registries, which collect data on quality measures from individual providers and group practitioners. 
PUBLISHED: May 26, 2018
Patel Provides Perspective on Immunotherapy Developments in NSCLC
Sandip P. Patel, MD, discusses existing and emerging immunotherapy approaches for patients with locally advanced and metastatic NSCLC.
PUBLISHED: May 25, 2018
COG Addresses Unmet Needs in Pediatric NHL
Birte Wistinghausen, MD, shares her insight on the potential for targeted therapies in the treatment of pediatric non-Hodgkin lymphoma, and the steps that the Children’s Oncology Group is taking to cure all patients with this disease.
PUBLISHED: May 25, 2018
FDA Delays Decision on Lenvatinib for HCC
The FDA has extended the review period for lenvatinib as a first-line treatment for patients with unresectable hepatocellular carcinoma. The new action date for the supplemental new drug application is August 24, 2018.
PUBLISHED: May 25, 2018
Latest Peer Exchange Discussions
MDS: The Current Understanding in Molecular Testing and Biomarkers
Panelists James M. Foran, MD, FRCPC, and Azra Raza, MD, provide insight on the current understanding in molecular testing and biomarkers in myelodysplastic syndrome. View Now
ALK-Positive Lung Cancer
Panelists Mark A. Socinski, MD; Gregory J. Riely, MD, PhD; Jared Weiss, MD; Thomas E. Stinchcombe, MD; and Benjamin P. Levy, MD; provide insight on the treatment options in ALK-positive lung cancer. View Now
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Community Practice Connections™: Optimizing Outcomes in HER2-Positive Breast Cancer: Emerging Evidence and Practical Strategies in Early-Stage Treatment SettingsMay 30, 20182.0
Community Practice Connections: New York GU™: 10th Annual Interdisciplinary Prostate Cancer Congress® and other Genitourinary MalignanciesMay 30, 20181.5
Publication Bottom Border
Border Publication